Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

BACKGROUND: Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase (MAPK) pathway with the MEK inhibitor, trametinib (Tra) have been limited by toxic...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Main Authors: Sriskandarajah, Priya, De Haven Brandon, Alexis, MacLeod, Kenneth, Carragher, Neil O., Kirkin, Vladimir, Kaiser, Martin, Whittaker, Steven R.
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2020
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106683/
https://ncbi.nlm.nih.gov/pubmed/32228485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06735-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares